FollowMyHealth Patient Portal

Garry Stuart Tobin, MD

Associate Professor, Medicine
Division of Endocrinology, Metabolism and Lipid Research

Specialty Areas

Internal Medicine
Endocrinology
Diabetes

Board Certifications

Endocrinology and Metabolism
Internal Medicine

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Diabetes, endocrinology, metabolism, internal medicine

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Diabetes Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 13
Office Phone: 314-747-7300
Fax: 314-747-7065

Education

Education

Fellowship: Endocrinology and Metabolism, Washington University School of Medicine, Barnes Hospital, St. Louis, Missouri 1990
Residency: Internal Medicine, Washington University School of Medicine, Barnes Hospital, St. Louis, Missouri 1988
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1985
B.S.: University of Missouri, Rolla, Missouri 1988

Publication & Research

Publication & Research

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB, DEVOTE Study Group.
N Engl J Med. 2017 Aug 24; 377(8)723-732. doi: 10.1056/NEJMoa1615692.

PMID:
    28605603
    [PubMed - indexed for MEDLINE]
Related citations


Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia.
Wheeler DT, Schafers SJ, Horwedel TA, Deal EN, Tobin GS
J Hosp Med. 2016 May; 11(5)355-7. doi: 10.1002/jhm.2545.

PMID:
    26762588
    [PubMed - in process]
Related citations


Safety and efficacy of hyperglycemia urgency order set.
Deal EN, Tobin GS, McGill JB
J Diabetes Sci Technol. 2014 Sep; 8(5)1062-3. doi: 10.1177/1932296814538236.

PMID:
    25172882
    [PubMed - indexed for MEDLINE]
Related citations


Prevention of inpatient hypoglycemia with a real-time informatics alert.
Kilpatrick CR, Elliott MB, Pratt E, Schafers SJ, Blackburn MC, Heard K, McGill JB, Thoelke M, Tobin GS
J Hosp Med. 2014 Oct; 9(10)621-6. doi: 10.1002/jhm.2221.

PMID:
    24898687
    [PubMed - indexed for MEDLINE]
Related citations


Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.
Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB
Int J Clin Pract. 2012 Dec; 66(12)1147-57. doi: 10.1111/ijcp.12032.

PMID:
    23061886
    [PubMed - indexed for MEDLINE]
Related citations


Prediction and prevention of treatment-related inpatient hypoglycemia.
Elliott MB, Schafers SJ, McGill JB, Tobin GS
J Diabetes Sci Technol. 2012 Mar 1; 6(2)302-9.

PMID:
    22538139
    [PubMed - indexed for MEDLINE]
Related citations


Inpatient insulin orders: are patients getting what is prescribed?
Deal EN, Liu A, Wise LL, Honick KA, Tobin GS
J Hosp Med. 2011 Nov; 6(9)526-9. doi: 10.1002/jhm.938.

PMID:
    22042479
    [PubMed - indexed for MEDLINE]
Related citations


Policy implementation for inpatient management of U-500 insulin resulting in lower incidence of hypoglycemia.
Deal EN, Tobin GS
Endocr Pract. 2011 May-Jun; 17(3)521.

PMID:
    21700563
    [PubMed - indexed for MEDLINE]
Related citations


Preventing hypoglycemia with novel technology and flexible therapy.
Dunai J, Tobin GS
Mo Med. 2011 Mar-Apr; 108(2)113-7.

PMID:
    21568233
    [PubMed - indexed for MEDLINE]
Related citations


A case of severe neuropathy associated with hypertriglyceridemia.
Hou R, Goldberg AC, Tobin GS
Endocr Pract. 2008 Nov; 14(8)1020-2.

PMID:
    19095603
    [PubMed - indexed for MEDLINE]
Related citations


Inpatient glycemic control on the vascular surgery service.
Theilen BM, Gritzke KA, Knutsen PG, Riek AE, McGill JB, Sicard GA, Tobin GS
Endocr Pract. 2008 Mar; 14(2)185-91.

PMID:
    18308656
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2016.

Company Name: Eli Lilly

Royalties:

Equity: No

Consulting/Advisory Board:

Speaker Fees: $25,001 - $50,000

Reporting Date: May 01, 2017


Company Name: NovoNordisk/Quintiles

Royalties:

Equity: No

Consulting/Advisory Board: $25,001 - $50,000

Speaker Fees:

Reporting Date: May 01, 2017